147 related articles for article (PubMed ID: 32711961)
1. Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?
Speir RW; Barboza MP; Calaway A; Masterson TA; Cary C; Koch M; Bihrle R; Cheng L; Adra N; Kaimakliotis H
Clin Genitourin Cancer; 2021 Feb; 19(1):47-52. PubMed ID: 32711961
[TBL] [Abstract][Full Text] [Related]
2. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
4. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
[TBL] [Abstract][Full Text] [Related]
5. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.
Kaimakliotis HZ; Monn MF; Cho JS; Pedrosa JA; Hahn NM; Albany C; Gellhaus PT; Cary KC; Masterson TA; Foster RS; Bihrle R; Cheng L; Koch MO
Future Oncol; 2016 Aug; 12(15):1795-804. PubMed ID: 27255805
[TBL] [Abstract][Full Text] [Related]
7. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
8. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic.
Bree KK; Kokorovic A; Westerman ME; Hensley PJ; Brooks NA; Qiao W; Shen Y; Kamat AM; Dinney CP; Navai N
J Urol; 2023 Jan; 209(1):140-149. PubMed ID: 36250944
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Utilization and Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced-urothelial Bladder Cancer (LABC)-Real World Data From an Indian Tertiary Care Cancer Center.
Saravanabavan S; Prakash GJ; Joshi A; Pal M; Gujela A; Arora A; Bakshi G; Prabhash K; Noronha V; Murthy V; Maitre P; Teja R
Clin Genitourin Cancer; 2023 Oct; 21(5):e326-e333. PubMed ID: 37211451
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
[TBL] [Abstract][Full Text] [Related]
11. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
[TBL] [Abstract][Full Text] [Related]
12. Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?
Shen HM; D'Souza AM; Green IF; Pohar KS; Mortazavi A; Zynger DL
Hum Pathol; 2015 Sep; 46(9):1367-75. PubMed ID: 26232112
[TBL] [Abstract][Full Text] [Related]
13. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
Mitra AP; Skinner EC; Miranda G; Daneshmand S
BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer.
Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H
Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093
[TBL] [Abstract][Full Text] [Related]
15. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.
Hellenthal NJ; Ramirez ML; Evans CP; Devere White RW
BJU Int; 2010 Feb; 105(4):485-8. PubMed ID: 19849694
[TBL] [Abstract][Full Text] [Related]
16. Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors.
Honma I; Masumori N; Sato E; Takayanagi A; Takahashi A; Itoh N; Tamagawa M; Sato MA; Tsukamoto T
Urology; 2004 Oct; 64(4):744-8. PubMed ID: 15491713
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
18. Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.
Mazza P; Moran GW; Li G; Robins DJ; Matulay JT; Herr HW; Decastro GJ; McKiernan JM; Anderson CB
J Urol; 2018 Nov; 200(5):1005-1013. PubMed ID: 29787740
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
[TBL] [Abstract][Full Text] [Related]
20. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
